To accelerate clinical trials of its precision cancer vaccines.
The Series A round, led by a group of French investors in association with Belgian investment funds, will be used to finance the first Phase I/IIA clinical trial of Brenus’ first candidate, STC-1010, in metastatic colorectal cancer, as well as the development of a second candidate in another solid tumor indication (STC-1020).